http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-4320677-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b10c5a760d03428721bb801301dd634c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70514 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2812 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate | 1993-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27b61c112664d4bcb2b0c6981711fdab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_745996fd468cce6a7b8daebad838e635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2766e38c5148341327e68ac97a0852d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e0987bf9b55a4a202064caba5332134 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6bd3ea5050524fa62398c877159993d1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eba4d05d77047c7a66e11e49996bdfeb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd5cbe3f7eda46e65a990735bf5ede32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39daeb0f1f91f2a715a96f53fd340747 |
| publicationDate | 1995-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | DE-4320677-A1 |
| titleOfInvention | Synthetic peptides to neutralize the infectivity of AIDS virus (HIV) |
| abstract | The invention relates to phenylalanine-containing peptides with the brief formula: R1-aa1-Tyr-Ile-aa4-aa5-Val-aa7-aa8-aa9-R2, where the radical R1 corresponds either to a hydrogen atom or R3. The radical R2 corresponds to a hydrogen group or a group which is the same as or different from R3, where R3 is an oligopeptide which contains 2 to 10 amino acid residues; aa1 is Tyr or Phe, aa4 is Cys or Phe, aa5 is Glu or Phe, aa7 is Glu or Phe, aa8 is Asp or Phe and aa9 is Gln, Glu or a single bond between aa8 and R2, with at least one of the groups aa1, aa4, aa5, aa7 and aa8 being Phe. The preferred structures are those in which R1 = H and R2 = OH and in which the peptide is readily soluble in water. These peptides can be used for inhibition of the infectiosity of the AIDS Virus. These peptides have possible therapeutic uses, not only for the actual AIDS disorder but also for disturbing concomitant manifestations of AIDS. They could be useful for bringing to a standstill the advance of the disorder in asymptomatic HIV-seropositive people. Accordingly, they may be effective for prophylaxis of infection in people in risk groups who may possibly come into contact with the virus, and in the newborn children of seropositive mothers. These peptides can be prepared synthetically by the solid-phase method of Merrifield or by genetic engineering methods. |
| priorityDate | 1993-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 60.